Shares of the company are trading at $0.80 just above the 50 day moving average of $0.75 and just a bit lower than the 200 day moving average of $0.87. The 50 day moving average went up $0.06 or +7.6695% and the 200 day average went down by -7.3458%. Trading was light with 6,182 shares changing hands by the end of trading on Tuesday. Trading volume was down 96.43% under the stocks average daily volume.
Investors are more bullish on TrovaGene, Inc. recently if you look at the motion in short interest. The firm experienced a fall in short interest from September 15, 2017 to September 29, 2017 of -16.56%. Short interest fell from 3,205,554 to 2,674,770 over that period. With short interest at 2,674,770 and short average daily volume at 182,826, the short-interest ratio is 15.0 and the percentage of shorted shares is 0.09% as of September 29.
Here are a few substantial investment firms who have updated their positions. Ubs Group Ag divested its holdings by selling 3,121 shares a decrease of 91.1%. Ubs Group Ag now controls 304 shares with a value of $0. The total value of its holdings decreased 100.0%. As of the end of the quarter Cutler Group LP had sold a total of 400 shares trimming its holdings by 36.4%. The value of the investment in TROV decreased from $1,000 to $0 decreasing 100.0% quarter to quarter.
As of quarter end Prospera Financial Services Inc had disposed of 5,875 shares trimming its stake by 4.4%. The value of the company’s investment in TrovaGene, Inc. went from $156,000 to $87,000 a change of $69,000 since the last quarter. As of quarter end Meeder Asset Management Inc had acquired a total of 1,018 shares growing its position 65.1%. The value of the investment in (TROV) went from $2,000 to $2,000 a change of 0.0% quarter over quarter.
As of the last earnings report the EPS was $-1.25 and is projected to be $-0.86 for the current year with 37,269,000 shares now outstanding. Next quarter’s EPS is forecasted at $-0.14 and the next full year EPS is projected to be $-0.73.
Trovagene, Inc. (TrovaGene), launched on September 21, 2009, is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. The Company has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer..